Malaysian Genomics partners De Cell to bring cell-gene therapy programme to market


Malaysian Genomics Resource Centre Bhd executive chairman Azri Azerai

KUALA LUMPUR: Malaysian Genomics Resource Centre Bhd's (MGRC) wholly-owned subsidiary MGRC Healthcare Sdn Bhd is collaborating with De Cell Bhd for the commercialisation of the former's cell-gene therapy programme.

In a statement, the genomics and biopharmaceutical specialist said it will provide technical and production support to optimise the operational efficiency and market deployment of the EXOGENETIX programme.

De Cell will take on the role of exclusive marketing partner, overseeing all promotional and trademark activities to amplify the programme's market presence and success.

"This collaboration underscores MGRC’s commitment to spearheading innovation and transforming healthcare outcomes through advanced biotechnologies.

"By combining MGRC Healthcare's production capabilities with De Cell's marketing acumen, this partnership is poised to significantly advance the reach and effectiveness of the EXOGENETIX programme," said Malaysian Genomics executive chairman Azri Azerai.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

China's factory, services activity growth slows in April
Samsung first-quarter profit up 10-fold on memory chip recovery
Ringgit opens slightly lower against US$ ahead of FOMC meeting
MKHOP makes Main Market debut at 63c/share
Growth momentum continues on Bursa
Wall St notches gain; yen surges, intervention suspected
Trading ideas: KLK, Capital A, AAX, UOA, YTL Hospitality, Malakoff, Sapura Energy, Oppstar
New accounting software not needed for e-invoicing
Govt promotes construction of social housing
AIA new business value soars 27%, adds US$2bil to buybacks

Others Also Read